Investigational drug · Phase 3
Plonmarlimab
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Gouty Arthritis, Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytoses.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
6
Any phase or sponsor naming "Plonmarlimab"
First trial start
2023
Apr 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Plonmarlimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Gouty Arthritis
- Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
- Hemophagocytic Lymphohistiocytoses
Approved drugs for the same conditions: Gout
Largest trials
Live from ClinicalTrials.gov: studies naming "Plonmarlimab" as an intervention, largest first.
- A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty ArthritisPivotal-lookingRecruiting
TJ Biopharma Co., Ltd.Industry
NCT07453004 · 170 participants (planned) · Start Mar 26, 2026 · Primary completion Dec 31, 2027
Drug: Plonmarlimab; Compound betamethasone and 2 more · For: Acute Gouty Arthritis
Sites: Bengbu, China; Chongqing, China; Jiangmen, China · 30 sites in all
- Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)Pivotal-lookingCompleted
I-Mab Biopharma US LimitedIndustry
NCT04341116 · 149 participants · Start Apr 11, 2020 · Primary completion Feb 7, 2022
Drug: TJ003234; Placebo · For: Coronavirus Disease 2019 COVID-19
Sites: Little Rock, Arkansas; Sylmar, California; Washington D.C., District of Columbia · 14 sites in all
- A Study of TJ003234 in Rheumatoid Arthritis PatientsStatus unknown
I-Mab Biopharma US LimitedIndustry
NCT04457856 · 63 participants (planned) · Start Aug 6, 2020 · Primary completion Mar 2023
Drug: TJ003234 injection · For: Rheumatoid Arthritis
Sites: Bengbu, China; Beijing, China; Nanjing, China · 5 sites in all
I-Mab Biopharma US LimitedIndustry
NCT03794180 · 32 participants · Start Mar 18, 2019 · Primary completion Sep 5, 2019
Drug: TJ003234; Placebo · For: Healthy Adult Subjects
Sites: Baltimore, Maryland
TJ Biopharma Co., Ltd.Industry
NCT07208058 · 30 participants (planned) · Start Nov 21, 2025 · Primary completion Dec 20, 2026
Drug: Plonmarlimab · For: Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
Sites: Beijing, China; Guangzhou, China; Nanning, China · 18 sites in all
TJ Biopharma Co., Ltd.Industry
NCT07034209 · 18 participants · Start Apr 7, 2023 · Primary completion Apr 18, 2025
Drug: Plonmarlimab · For: Hemophagocytic Lymphohistiocytoses
Sites: Beijing, China; Shanghai, China; Nanjing, China · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Plonmarlimab, a GM-CSF-neutralizing antibody, for macrophage activation syndrome.
Wang J, Wang R, Wang Q, et al. · J Hematol Oncol 2026
- Thrombotic thrombocytopenic purpura and macrophage activation syndrome secondary to Sjögren's syndrome: a case report.
Liu X, Liu M, Yao M, et al. · Front Immunol 2026
- Plonmarlimab, a novel anti-GM-CSF blocking antibody, ameliorates disease progression in the pre-clinical model of macrophage activation syndrome.
Ding J, Xu K, Niu Y, et al. · Immunology 2024
Also in development for Acute Gouty Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.